Nebivolol 5 mg (DrugBank: Nebivolol)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
17 | Multiple system atrophy | 1 |
113 | Muscular dystrophy | 0 |
167 | Marfan syndrome | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01044693 (ClinicalTrials.gov) | January 2010 | 6/1/2010 | Nebivolol in the Supine Hypertension of Autonomic Failure | Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg | Vanderbilt University | Forest Laboratories | Completed | 18 Years | 80 Years | All | 20 | N/A | United States |